DC 7703 · 38 CFR 4.117
Leukemia C&P Exam Prep
To evaluate the current severity, treatment requirements, and functional impact of leukemia for VA disability compensation purposes under 38 CFR 4.117, DC 7703. The examiner will document disease status (active vs. remission), treatment history and current regimen, laboratory values, and any complications or residual effects.
- Format:
- Interview + Physical
- Typical duration:
- 30-45 minutes
- DBQ form:
- Hematologic_and_Lymphatic_Conditions_Including_Leukemia (Hematologic_and_Lymphatic_Conditions_Including_Leukemia)
- Examiner:
- Hematologist or Oncologist
What the examiner evaluates
- Specific leukemia type (CLL, CML, AML, ALL, hairy cell, chronic granulocytic, etc.)
- Disease status: active, in remission, or in treatment phase
- Current and prior treatment modalities (chemotherapy, biologic therapy, myelosuppressive therapy, interferon, transplant)
- Frequency and severity of infections secondary to immunosuppression
- Blood count laboratory values (CBC with differential, platelet count, hemoglobin, hematocrit, RBC, WBC)
- Bone marrow or peripheral blood stem cell transplant history
- Whether continuous biologic or myelosuppressive therapy is required
- Functional limitations and impact on daily life and employment
- Comorbidities and secondary conditions related to leukemia or its treatment
Exam is typically conducted in person by a hematologist or oncologist. Bring all oncology and hematology records. The examiner will review laboratory values and treatment records in detail. You have the right to request recording of the exam in most states - confirm your state law before the appointment.
Measurements and tests
Complete Blood Count (CBC) with Differential
What it measures: White blood cell count, red blood cell count, hemoglobin, hematocrit, platelet count, and WBC differential - all critical for leukemia rating criteria
What to expect: Blood draw results from recent labs (within 90 days preferred). Examiner will review most recent values and document them on the DBQ. Bring printed copies of your most recent lab reports.
Critical thresholds
- WBC significantly elevated or suppressed Helps establish active disease vs. remission and supports treatment necessity documentation
- Platelet count at or below 30,000 Supports higher-severity ratings related to thrombocytopenic complications
- Platelet count 30,001-50,000 Intermediate severity marker for rating purposes
- Hemoglobin severely reduced Supports anemia as a complication requiring separate or combined evaluation
Tips
- Bring the actual printed lab reports - do not rely solely on the examiner having access to records
- If your counts fluctuate, bring labs showing your worst values in the past 12 months
- Note the date of each lab draw clearly so the examiner can document the date alongside each value
- If you require growth factor support to maintain counts, bring documentation of that treatment
Pain considerations: Laboratory values alone do not capture the full functional burden. Be prepared to verbally describe fatigue, weakness, and functional limitations associated with abnormal blood counts.
Bone Marrow Biopsy or Aspiration Results
What it measures: Bone marrow cellularity, blast percentage, and disease activity - central to confirming remission status or active disease
What to expect: Examiner will review pathology reports. Bring copies of all bone marrow biopsy results with dates and findings.
Critical thresholds
- Residual or recurrent disease on biopsy Supports active disease classification and highest-tier ratings
- Complete remission on biopsy May affect rating level - ensure treatment burden and residual symptoms are fully documented even in remission
Tips
- Bring the full pathology report, not just a summary
- If biopsy showed remission but you are still on continuous therapy, emphasize that treatment is ongoing
- Note how the biopsy procedure itself affects you - pain, recovery time, anxiety
Pain considerations: Bone marrow biopsies are painful procedures. Accurately describe the procedural burden and recovery to your examiner as part of your overall treatment narrative.
Molecular and Genetic Markers (e.g., BCR-ABL for CML, FISH, PCR)
What it measures: Minimal residual disease, chromosomal abnormalities, and treatment response at the molecular level
What to expect: Examiner may review molecular testing results to determine remission depth (e.g., complete molecular response) and to classify CML phase (chronic, accelerated, blast).
Critical thresholds
- Detectable BCR-ABL or other molecular marker despite therapy Indicates continued disease activity even if CBC appears normal; supports ongoing treatment necessity
- Undetectable molecular marker on continuous targeted therapy May support 'apparent remission on continuous molecularly targeted therapy' classification for CML
Tips
- Bring all molecular monitoring test results with dates
- For CML veterans, document whether you are on continuous tyrosine kinase inhibitor (TKI) therapy and whether discontinuation has been attempted or is medically inadvisable
- If your oncologist has stated that lifelong therapy is required, ask for a written statement to that effect
Pain considerations: Side effects of TKIs and targeted therapies (fatigue, musculoskeletal pain, fluid retention, GI symptoms) should be described in detail as part of your overall symptom picture.
Rating criteria by percentage
100%
Active leukemia - active disease requiring treatment, including active disease during treatment phase, or active disease requiring bone marrow or peripheral blood stem cell transplant. Under 38 CFR 4.117 and General Rating Formula for Hematologic and Lymphatic Conditions, a 100% rating applies to active leukemia requiring continuous biologic therapy or myelosuppressive therapy, or requiring bone marrow/stem cell transplant. Note: A minimum 1-year 100% rating is assigned following transplant.
Key symptoms
- Active leukemia confirmed by laboratory or biopsy
- Currently undergoing chemotherapy, immunotherapy, biologic therapy, or myelosuppressive therapy
- Requiring or having undergone bone marrow or peripheral blood stem cell transplant
- Severe fatigue precluding even light manual labor
- Recurrent serious infections requiring hospitalization
- Profound cytopenias (severe anemia, thrombocytopenia, neutropenia)
- Complete functional impairment
From 38 CFR: Active leukemia requiring continuous biologic therapy or myelosuppressive therapy = 100%. Active disease requiring bone marrow or stem cell transplant = 100% (minimum 1 year post-transplant). CML in apparent remission on continuous molecularly targeted therapy is rated under the CML criteria which may still yield 100% if continuous therapy is required.
100%
CML (Chronic Myeloid/Myelogenous Leukemia) in apparent remission on continuous molecularly targeted therapy - still rated 100% if continuous molecularly targeted therapy (e.g., TKI such as imatinib, dasatinib) is required to maintain remission. Rate intermittent myelosuppressive therapy or molecularly targeted therapy at lower levels.
Key symptoms
- On continuous TKI or targeted therapy with no interruption
- Molecular monitoring ongoing (PCR, FISH testing)
- Side effects of continuous therapy (fatigue, fluid retention, GI distress, musculoskeletal pain)
- Unable to discontinue therapy without risk of relapse as documented by oncologist
From 38 CFR: CML in apparent remission on continuous molecularly targeted therapy = 100%. CML requiring intermittent myelosuppressive or molecularly targeted therapy = lower rating. See also DC 7703 cross-reference to General Rating Formula for Hematologic Conditions.
60%
Leukemia in remission but requiring intermittent treatment - includes intermittent myelosuppressive therapy, intermittent molecularly targeted therapy, requiring intermittent use of myeloid growth factors, or infections recurring on average at least once every three months per 12-month period. Also applies to CLL or other B-cell leukemia complete remission with residual functional impact at this level.
Key symptoms
- Leukemia in remission but requiring intermittent chemotherapy or targeted therapy
- Infections recurring on average at least once every three months per 12-month period
- Requiring intermittent myeloid growth factors (G-CSF, GM-CSF) to maintain counts
- Requiring 1-3 blood or platelet transfusions per 12-month period
- Significant fatigue limiting work capacity to light manual labor only
- Residual immunosuppression with documented recurrent infections
From 38 CFR: Leukemia in remission requiring intermittent myelosuppressive or molecularly targeted therapy = 60%. Infections recurring on average at least once every three months per 12-month period = 60%. Requiring intermittent myeloid growth factors = 60%.
30%
Leukemia in remission with residual lower-level treatment requirements - includes continuous medication (e.g., antibiotics) for infection control, infections recurring on average at least once per 12-month period, or requiring continuous medication but not myelosuppressive/biologic therapy. Functional limitations are present but less severe.
Key symptoms
- Leukemia in confirmed remission
- Requiring continuous medication such as prophylactic antibiotics for infection control
- Infections recurring on average at least once per 12-month period but less frequently than every 3 months
- Some fatigue affecting capacity for heavy labor but able to perform light work
- Residual effects of prior treatment (neuropathy, fatigue, immune compromise)
From 38 CFR: Leukemia in remission requiring continuous medication such as antibiotics for infection control = 30%. Infections recurring on average at least once per 12-month period = 30%.
0%
Leukemia in complete remission with no current treatment requirements and no significant residual symptoms - asymptomatic with no medication required for control of the condition. Note: A non-compensable (0%) rating is still service-connected, preserving future claims for worsening and establishing eligibility for certain VA benefits.
Key symptoms
- Complete remission confirmed
- No ongoing treatment required
- No recurrent infections
- No significant functional limitations attributable to leukemia
- Laboratory values within normal limits
From 38 CFR: Asymptomatic leukemia in remission requiring no treatment = 0% (non-compensable but service-connected). Veterans should still document any residual effects of prior treatment, as these may support a higher evaluation.
Describing your symptoms accurately
Fatigue and Energy Level
How to describe it: Describe fatigue as it affects your worst days - not your average or best days. Quantify how many hours per day you can be active before exhaustion, whether you need daytime naps, and how fatigue has changed your work capacity, household functioning, and social participation. Use concrete comparisons (e.g., 'Before leukemia I could work 8-hour shifts; now I am exhausted after 2 hours of light activity').
Example: On my worst days - which occur approximately 2-3 times per week - I am unable to get out of bed for more than 4 hours total. I cannot drive, prepare meals, or perform basic household tasks without needing to lie down. The fatigue is not relieved by rest and has been present continuously since beginning chemotherapy.
Examiner listens for: Frequency and duration of severe fatigue episodes, impact on employment and activities of daily living, whether fatigue is treatment-related or disease-related or both, and any objective documentation such as employer accommodations or reduced work hours.
Avoid: Saying 'I get a little tired' or 'I manage okay' when you are actually unable to sustain full-time employment or normal daily activities. Do not minimize fatigue because you are still functional on good days.
Infection History and Frequency
How to describe it: Provide a specific accounting of every infection in the past 12 months - dates, type of infection (e.g., pneumonia, bacteremia, UTI, cellulitis), treatment required (outpatient antibiotics vs. hospitalization), and duration of illness. The rating criteria specifically hinge on infection frequency (once per 12 months = 30%; once every 3 months = 60%; hospitalizations 1-2 times = higher tier; 3+ hospitalizations = highest tier).
Example: In the past 12 months I have had four infections: a hospitalization for pneumonia in January lasting 5 days, an outpatient URI requiring antibiotics in April, a skin infection requiring IV antibiotics in July, and a fever of unknown origin requiring emergency evaluation and hospitalization in October. I take prophylactic antibiotics daily and still experience recurring infections.
Examiner listens for: Exact number of infections, whether hospitalization was required, what organisms were involved, whether prophylactic antibiotics are ongoing, and whether immunocompromise from leukemia or its treatment is documented as the cause of recurrent infections.
Avoid: Forgetting to mention infections that seemed minor at the time, or omitting ER visits that did not result in overnight hospitalization. Also do not fail to mention that you are on continuous prophylactic antibiotics - this alone supports a 30% rating floor.
Treatment Burden and Current Regimen
How to describe it: Describe every current medication and procedure related to your leukemia treatment - oral targeted therapy (TKIs), IV chemotherapy cycles, biologic injections, growth factor injections, blood or platelet transfusions, and monitoring procedures. Specify whether treatment is continuous (daily, weekly) or intermittent (monthly, quarterly cycles). Describe side effects that affect daily functioning.
Example: I take imatinib 400mg daily without interruption. I cannot discontinue this medication without my oncologist's guidance because doing so risks disease progression. I receive monthly blood draws and quarterly molecular monitoring. Side effects include daily nausea, fluid retention in my legs, muscle cramps that wake me at night 3-4 times per week, and chronic fatigue that limits me to approximately 4 hours of productive activity per day.
Examiner listens for: Whether therapy is continuous vs. intermittent, the specific drugs and doses, whether therapy is myelosuppressive or biologic, side effect burden, frequency of monitoring visits, and whether the veteran's oncologist has documented the medical necessity of ongoing treatment.
Avoid: Saying 'I just take a pill every day' when that pill is a continuous molecularly targeted therapy required to maintain remission - this distinction is critical for CML rating at 100%. Always specify the drug name and document that it is continuous and cannot be stopped.
Functional Impact on Work and Daily Life
How to describe it: Describe specifically what you can and cannot do as a result of your leukemia, treatment side effects, and associated symptoms. Address physical labor capacity, cognitive functioning (chemo brain), emotional health, ability to maintain employment, and any accommodations or job changes made because of your condition.
Example: I was a construction foreman prior to my leukemia diagnosis. I have been unable to return to physical labor since beginning treatment. I currently work part-time as a desk clerk - 20 hours per week maximum - because fatigue and frequent medical appointments prevent full-time work. I have lost over 40 pounds. I am unable to lift more than 10 pounds, cannot stand for more than 30 minutes without needing to sit, and have cognitive difficulties remembering instructions and completing complex tasks.
Examiner listens for: Occupational impact, activities of daily living limitations, cognitive effects, whether the veteran meets the criteria for 'symptoms preclude other than light manual labor' or 'symptoms preclude even light manual labor,' and the overall functional burden documented on the DBQ's impact section.
Avoid: Underreporting cognitive effects (chemo brain), emotional/psychiatric impact, or changes in employment. Do not say you are 'doing fine at work' if you have had to reduce hours, change jobs, or receive accommodations.
Transplant History and Post-Transplant Status
How to describe it: If you have undergone bone marrow or peripheral blood stem cell transplant, provide exact dates of hospital admission, transplant date, and hospital discharge. Describe the ongoing post-transplant monitoring, immunosuppressive medications required post-transplant, graft-versus-host disease (GVHD) if present, and any complications or residual effects.
Example: I underwent allogeneic bone marrow transplant on [date] and was hospitalized for 47 days. Since discharge I have required continuous immunosuppressive therapy for graft-versus-host disease affecting my skin and GI tract. I attend transplant clinic monthly. I remain profoundly immunocompromised and have been hospitalized twice in the past year for infections. I am unable to work and require assistance with daily activities.
Examiner listens for: Exact transplant dates, type of transplant (autologous vs. allogeneic, bone marrow vs. peripheral blood), whether a minimum 1-year 100% rating period applies, current post-transplant treatment requirements, and any GVHD complications requiring separate evaluation.
Avoid: Failing to bring hospital admission and discharge records for the transplant. Also do not fail to mention GVHD - it may be a separately ratable condition or may support continuation of high-level ratings beyond the initial post-transplant period.
Common mistakes to avoid
Describing symptoms on your average or best day rather than your worst day
Why: VA rating criteria under M21-1 guidance require evaluation of the condition at its worst - describing only average functioning systematically underrepresents your actual disability level
Do this instead: Explicitly state 'On my worst days, which occur [frequency]...' and describe the full severity of those episodes. Bring a symptom diary or journal documenting bad days with dates.
Impact: All levels - particularly the difference between 60% and 100%
Failing to specify whether treatment is continuous or intermittent
Why: For CML and other leukemias, the distinction between continuous and intermittent therapy is the single most important factor separating a 100% rating from a 60% rating under the rating schedule
Do this instead: Explicitly state 'I take [drug name] every day without interruption' or 'I receive IV chemotherapy in cycles every [X] weeks.' Bring medication bottles, pharmacy printouts, and infusion records. Ask your oncologist for a letter confirming continuous therapy is medically required.
Impact: Difference between 60% and 100%
Not bringing printed lab results to the exam
Why: The DBQ requires specific documented laboratory values including WBC, WBC differential, RBC count, hemoglobin, hematocrit, and platelet count with dates. If the examiner cannot access your records electronically, these fields may be left blank or estimated.
Do this instead: Print or download your most recent CBC with differential, your worst CBC results from the past 12 months, and any bone marrow or molecular monitoring results. Organize them chronologically in a folder.
Impact: All levels - missing lab values can prevent accurate rating
Not reporting all infections, including those treated outpatient
Why: The rating criteria specifically count infection frequency per 12-month period. Veterans often forget minor infections treated with antibiotics, but these count toward the threshold for 30% vs. 60% ratings.
Do this instead: Before the exam, review your records and create a written list of every infection episode in the past 12 months with approximate dates, symptoms, treatment (antibiotic course vs. ER visit vs. hospitalization), and duration.
Impact: Difference between 30% and 60%
Downplaying remission status without documenting treatment burden
Why: Veterans sometimes assume that being 'in remission' means they are not disabled, when in fact continuous therapy required to maintain remission (especially for CML on TKIs) still warrants 100% rating under the rating schedule
Do this instead: Even if your oncologist says you are in remission, document every medication, every side effect, every monitoring appointment, and every treatment that is ongoing. Remission on continuous therapy is not the same as no disability.
Impact: Difference between 0% and 100%
Forgetting to mention transplant hospitalization dates
Why: Post-transplant rating requires documentation of the exact hospitalization dates. A minimum 1-year 100% rating follows transplant, but only if the dates are documented in the DBQ. Missing dates may result in the evaluator being unable to assign this rating.
Do this instead: Bring copies of the hospital admission and discharge paperwork for your transplant hospitalization. The DBQ specifically asks for date of hospital admission and date of discharge after transplant.
Impact: 100% (post-transplant minimum rating period)
Not addressing secondary conditions separately
Why: Leukemia treatment can cause peripheral neuropathy, avascular necrosis, cardiac toxicity, secondary cancers, cognitive impairment, and other conditions that may be separately ratable as secondary service-connected disabilities - dramatically increasing combined rating
Do this instead: List every health condition you have developed since your leukemia diagnosis or treatment. Ask your treating providers to document the relationship between those conditions and your leukemia or its treatment. File secondary claims for each one.
Impact: Combined rating - indirect impact across all rating levels
Prep checklist
- critical
Gather all hematology and oncology records
Collect records from every oncologist, hematologist, and treatment facility that has cared for you. Include initial diagnosis records, all biopsy reports (bone marrow and peripheral blood), all CBC lab results (prioritize the most recent and the most abnormal values), all treatment records showing chemotherapy cycles or continuous TKI therapy, and any transplant hospitalization records with admission and discharge dates.
before exam
- critical
Print your most recent and most abnormal laboratory results
The DBQ specifically requires: WBC count with date, WBC differential with date, RBC count with date, hemoglobin (g/100mL) with date, hematocrit with date, and platelet count with date. Bring both your most recent values AND the worst values from the past 12 months. Label each printout clearly.
before exam
- critical
Document your complete medication list with dosing and frequency
Create a written list of every medication you take for leukemia or as a result of leukemia treatment. Include drug name, dose, frequency, and whether it is taken continuously or intermittently. Highlight myelosuppressive agents, biologic therapies, TKIs, immunosuppressants, prophylactic antibiotics, and growth factors. The examiner will document these for the rating determination.
before exam
- critical
Create a written infection log for the past 12 months
List every infection episode in the past 12 months: approximate date, type of infection, symptoms, treatment required (oral antibiotics, IV antibiotics, ER visit, hospitalization with admission/discharge dates), and duration. This directly maps to specific rating criteria thresholds. Bring supporting medical records for any hospitalizations.
before exam
- critical
Obtain a supporting letter from your treating oncologist or hematologist
Ask your oncologist to write a letter documenting: (1) your specific leukemia type and ICD-10 code; (2) current disease status (active vs. remission); (3) whether continuous therapy is medically required and cannot be stopped; (4) treatment history including transplant dates if applicable; (5) prognosis; and (6) any functional limitations directly caused by the condition or its treatment. This letter can be decisive.
before exam
- critical
Prepare a written symptom narrative covering your worst days
Write 1-2 paragraphs describing your symptoms on your worst days. Address fatigue (hours of function, need for rest), infection susceptibility, treatment side effects, functional limitations (work, household tasks, social activities), cognitive effects, and emotional health impact. Practice reading it aloud - you should be able to summarize it in 2-3 minutes if asked.
before exam
- recommended
Research and document all secondary conditions
Identify every health condition you have developed since leukemia diagnosis or treatment: neuropathy, cardiac problems, cognitive issues, secondary infections, avascular necrosis, secondary cancers, psychological conditions. These may support secondary service connection claims and should be mentioned to the examiner as related conditions.
before exam
- recommended
Confirm your right to record the examination
Research your state law regarding one-party vs. two-party consent for recording. In most states, veterans may record their C&P examination. Notify the examiner at the start of the exam that you will be recording. Bring a recording device (smartphone with recording app). A recording protects you if the DBQ does not accurately reflect what was discussed.
before exam
- critical
Bring transplant hospitalization documentation if applicable
If you underwent bone marrow or peripheral blood stem cell transplant, bring the hospital admission document, transplant procedure report, and hospital discharge summary with exact dates. The DBQ specifically asks for these dates and they trigger the minimum 1-year 100% rating period.
before exam
- recommended
Review the specific leukemia type and confirm the correct ICD-10 code with your oncologist
The DBQ has separate entries for CLL, CML, CGL, hairy cell leukemia, and other B-cell leukemias, each with specific rating criteria. Knowing exactly which type of leukemia you have and its ICD-10 code ensures the examiner selects the correct section of the DBQ. Common codes: CML = C92.10, CLL = C91.10, AML = C92.00, ALL = C91.00, Hairy cell = C91.40.
before exam
- critical
Arrive with all documents organized in a folder
Bring two sets of copies: one to give the examiner if needed, one to keep. Organize chronologically: diagnosis records, treatment history, current medications, lab results (most recent first), infection log, and oncologist support letter. Having organized records demonstrates thoroughness and ensures the examiner has what they need.
day of
- critical
Do not downplay your symptoms on the day of the exam
The exam should reflect your typical experience and your worst days - not how you feel on exam day if today happens to be a relatively better day. If you are having a better day than usual, explicitly tell the examiner: 'Today is not a typical day for me - on a typical or bad day my symptoms are...' Then describe your worst-day experience.
day of
- recommended
Inform the examiner of your intent to record if applicable
At the start of the exam, calmly state: 'I would like to inform you that I will be recording this examination.' Place your recording device visibly. This is your right in most states. Do not be confrontational - simply state it as a matter of course.
day of
- critical
Be specific about treatment continuity when asked about medications
When the examiner asks about your medications, explicitly state whether each therapy is taken continuously every day or in intermittent cycles. The word 'continuous' is legally significant in the rating criteria. Say 'I take [drug] every day continuously without interruption' or 'I receive infusions every 21 days in recurring cycles.'
during exam
- critical
Report all symptoms including those you consider minor or unrelated
Mention every symptom, side effect, and health change since your leukemia diagnosis or treatment, even if you think it is unrelated. Let the examiner determine relevance. This includes: fatigue, neuropathy, cognitive changes, mood changes, weight changes, pain, GI symptoms, skin changes, cardiovascular symptoms, and any functional limitations.
during exam
- critical
Describe functional impact on work and daily activities explicitly
The DBQ has a dedicated section on functional impact. Proactively address: (1) current employment status and any changes due to leukemia; (2) activities you can no longer perform; (3) activities you perform with difficulty or need help with; (4) how many hours per day you can be productively active; (5) whether you require light vs. no manual labor limitations.
during exam
- recommended
Correct inaccuracies during the exam if you notice them
If the examiner records something inaccurately or misunderstands your description, politely correct it in real time. Say: 'I want to clarify - what I meant was...' It is much harder to correct a completed DBQ after the fact than to clarify during the exam.
during exam
- critical
Request a copy of the completed DBQ
After the exam, you have the right to request a copy of the completed DBQ. Submit a FOIA request or request through your VSO if needed. Review it carefully against your symptom narrative and medical records. If the DBQ contains significant inaccuracies or omissions, work with your VSO or accredited claims agent to submit a statement in rebuttal.
after exam
- recommended
File a buddy statement or personal statement if the DBQ is inaccurate
If the completed DBQ does not accurately reflect your symptoms, treatment burden, or functional limitations, submit a personal statement (VA Form 21-4138) or buddy statements from family members or caregivers who observe your daily limitations. Submit these to your claims file as soon as possible.
after exam
- recommended
Review your VA claim file for the DBQ and any additional development letters
Monitor your VA.gov account for the completed DBQ and any letters requesting additional evidence. Respond promptly to any development letters. If a rating decision is issued that you believe is incorrect, consult with a VSO or accredited claims agent about whether to request a Higher-Level Review, file a Supplemental Claim, or appeal to the Board of Veterans Appeals.
after exam
Your rights during a C&P exam
- You have the right to request a copy of the completed DBQ examination report after it is finalized - submit a request through your VSO or via FOIA to the VA Regional Office.
- In most states, you have the right to record your C&P examination - research your state's consent laws and inform the examiner at the start of the exam that you will be recording.
- You have the right to submit a personal statement (VA Form 21-4138) clarifying or correcting the record if you believe the DBQ does not accurately reflect your condition.
- You have the right to submit a private medical opinion or Nexus letter from your own treating oncologist or hematologist to supplement or rebut the C&P examination findings.
- You have the right to bring a VSO representative, accredited claims agent, or accredited attorney to your C&P examination as an observer (though they may not participate in the examination itself - confirm current VA policy).
- You have the right to request a new C&P examination if you believe the original examination was inadequate - this is typically raised through a Higher-Level Review or Supplemental Claim.
- You have the right to a Higher-Level Review, Supplemental Claim, or Board of Veterans Appeals review if you disagree with the rating decision that follows this examination - each pathway has specific evidence and procedural requirements.
- You have the right to have all relevant evidence in your VA claims file reviewed before a rating decision is made - ensure your oncology records, lab results, and supporting letters are submitted to your claims file before the exam.
- You have the right to request an earlier effective date if evidence shows your leukemia was service-connected prior to the date of your claim - work with a VSO or accredited representative to evaluate potential earlier effective dates.
- Under the PACT Act, veterans with certain leukemia diagnoses (particularly AML, ALL, and CLL) who were exposed to burn pits, Agent Orange, or certain radiation exposures may have presumptive service connection - confirm your presumptive eligibility with a VSO before your exam.
Related conditions
- Chronic Myeloid Leukemia (CML) Specific leukemia subtype rated under DC 7703 with unique criteria for continuous molecularly targeted therapy and apparent remission on TKI therapy
- Chronic Lymphocytic Leukemia (CLL) Specific leukemia subtype rated under DC 7703; CLL staging (Rai Stage 0 = asymptomatic) affects rating level selection on the DBQ
- Myelodysplastic Syndromes (MDS) DC 7725 - MDS that progresses to leukemia is evaluated as leukemia under DC 7703; also rated under the General Rating Formula for Hematologic Conditions
- Polycythemia Vera DC 7704 - if polycythemia vera undergoes leukemic transformation, it is evaluated as leukemia under DC 7703
- Aplastic Anemia DC 7716 - shares treatment modalities (bone marrow transplant, immunosuppressive therapy, growth factors) with leukemia; may be a comorbid or secondary condition
- Peripheral Neuropathy Frequently develops as a secondary condition due to chemotherapy neurotoxicity (vincristine, taxanes, platinum agents); separately ratable as a secondary service-connected disability
- Immune Thrombocytopenia (ITP) DC 7681 - may develop secondary to leukemia or its treatment; platelet count thresholds are shared rating criteria elements; separately ratable
- Acquired Hemolytic Anemia DC 7671 - may develop as a complication of CLL or treatment; separately ratable under the hematologic rating schedule
- Secondary Malignancy Treatment-related secondary cancers (e.g., therapy-related MDS or AML from prior chemotherapy or radiation) may be separately ratable as secondary service-connected conditions
- Depression and Anxiety (Cancer-Related) Mental health conditions secondary to a leukemia diagnosis are common and separately ratable under 38 CFR 4.130; file separately for maximum combined disability rating
- Graft-Versus-Host Disease (GVHD) Develops following allogeneic bone marrow or stem cell transplant; multi-organ manifestations (skin, GI, liver, lungs) are separately ratable as secondary service-connected conditions following leukemia treatment
Get a personalized prep packet
This guide covers what to expect for any veteran with this condition. If you have already uploaded your medical records, sign in to generate a packet that maps your specific symptoms to the DBQ fields your examiner will fill out.
This C&P exam preparation guide is for educational purposes only and does not constitute legal, medical, or claims advice. Always consult with a qualified Veterans Service Organization (VSO) representative or VA-accredited attorney for guidance specific to your claim. Never exaggerate, minimize, or fabricate symptoms during a C&P examination.